Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Plasma cell 4Other neoplasm 2Lymphoid 1

Conditions

Leukemia 14Leukemia, Myeloid, Acute 9Congenital Abnormalities 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 5Myeloproliferative Disorders 4Multiple Myeloma 4Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Lymphocytic, Chronic, B-Cell 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Precancerous Conditions 2Polycythemia Vera 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2Monoclonal Gammopathy of Undetermined Significance 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Prolymphocytic 2

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Cytogenetic Analysis × Clear all
NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
54 enrolled 13 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
45 enrolled 8 charts
Plasma cell

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00900263 2016-10-07

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

SWOG Cancer Research Network

Completed
375 enrolled
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions

NCT00898066 2015-03-06

S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

SWOG Cancer Research Network

Completed
37 enrolled
LymphoidOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Lymphoma, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡